March 2 (Reuters) - Oyster Point Pharma Inc  OYST.O :
    * OYSTER POINT PHARMA ANNOUNCES FDA ACCEPTANCE FOR FILING
NEW DRUG
APPLICATION FOR OC-01 (VARENICLINE) NASAL SPRAY FOR THE
TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE
    * OYSTER POINT PHARMA INC - PRESCRIPTION DRUG USER FEE ACT
(PDUFA)
TARGET ACTION DATE IS OCTOBER 17, 2021
    * OYSTER POINT PHARMA INC - U.S. FDA HAS STATED THAT IT DOES
NOT
INTEND TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS NASAL
SPRAY APPLICATION
    * OYSTER POINT PHARMA INC - PLANNED U.S. LAUNCH OF OC-01
(VARENICLINE) NASAL SPRAY IN Q4 OF 2021, IF APPROVED BY FDA

Source text for Eikon:  ID:nGNX8S4sBB 
Further company coverage:  OYST.O 

 ((Reuters.Briefs@thomsonreuters.com;))